Advancements in Brain Tumor Research
Development of a 3D Laboratory Model
Researchers have successfully created a three-dimensional laboratory model of brain tumors aimed at enhancing the development of new therapies in neuro-oncology. The process of drug development is typically resource-intensive, with an average cost exceeding one billion dollars to bring a new drug to market. In specialized fields like neuro-oncology, where treatments often require personalized approaches, these costs can be even more significant.
Challenges in Glioblastoma Treatment
The treatment outcomes for glioblastoma, recognized as the most aggressive form of brain cancer, have shown little improvement in recent years. Patients diagnosed with this condition have a median survival rate of only 15 months, highlighting the urgent need for more effective therapeutic strategies.
Innovative Drug Testing Methodology
To address the challenges in drug development, a collaborative team of researchers, including scientists from Johns Hopkins University and the Mayo Clinic, has developed a pluripotent stem cell model specifically for testing drugs targeting glioblastoma. This model features a combination of neurons and glioblastoma tumor cells arranged in a spherical structure. When paired with a proprietary histology platform, it facilitates rapid and precise measurements of drug efficacy.
Key Findings from the Research
The findings from this research were recently published in the Scientific Reports section of Nature. The research team evaluated two chemotherapeutic agents for glioblastoma using the three-dimensional cellular matrix. Their system successfully identified antitumor responses to temozolomide (TMZ), the standard first-line treatment for glioblastoma, as well as the experimental drug doxorubicin. Notably, the in vitro TMZ response was closely aligned with the well-established effects of TMZ in vivo.
Future Implications for Drug Development
The researchers are optimistic that this innovative system can help mitigate some inefficiencies associated with drug development for brain tumor treatments. The spherical cell structure is believed to more accurately mimic real human tumors compared to traditional mouse models. Additionally, it offers the potential for personalized therapies through the utilization of patient-derived cell lines.
Reference
Plummer S et al. A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. Sci Rep. 2019 Feb 5;9(1):1407. doi: 10.1038/s41598-018-38130-0.